Skip to main content
. 2023 Jan 1;13(1):278–294. doi: 10.7150/thno.77918

Table 3.

Transcriptional effects and leading-edge genes of extracted KEGG pathways in MPC tumors responding differentially to [PRRT] and [ET + PRRT]

MPC tumors [PRRT]↑↓ vs. [Control] (day 10) [ET + PRRT]↑↓ vs. [Control] (day 10) [ET]↑↓ vs. [Control] (day 4)
AV tumor 24h = 4.05 MBq/mL AV tumor 24h = 4.48 MBq/mL
Extracted KEGG pathway nes (fdr) Leading-edge genes (top 10) nes (fdr) Leading-edge genes (top 10) nes (fdr) Leading-edge genes
Central carbon metabolism in cancer ↓ ‒1.5 (0.10) Pdk1, ↓Slc2a1 ↑ 1.3 (0.23) Slc1a5 ↑ 1.8 (< 0.05) # Hk2
Arginine and proline metabolism ↓ ‒1.4 (0.21) Arg1, ↓P4ha1 P4ha3 ↑ 1.3 (0.22)
Citrate cycle (TCA cycle) ↑ 1.8 (0.06) ↑ 1.5 (0.09)
Glycolysis / Gluconeogenesis Pgk1 ↑ 1.3 (0.20) ↑ 2.1 (< 0.05) # Aldoc, ↑Hk2
Transcriptional misregulation in cancer Ccnd2, ↑Tgfbr2, ↑Spint1 ↑ 1.6 (0.06) Ngfr, ↑Etv4, ↑Baiap3, ↑Runx1, *↑Tgfbr2, *↑Ccnd2 ↓ ‒1.3 (0.21) Igf1
Pathways in cancer ↑ 1.6 (0.09) Cxcl12, ↑Mmp2, ↑Ccnd2, ↑Gli1, ↑Tgfbr2 ↑ 1.7 (< 0.05) *↑Mmp2, *↑Cxcl12, ↑Tcf7, ↑Hhip, ↑Jag2, ↑Axin2, ↑Runx1, ↑Lama5, *↑Tgfbr2, *↑Ccnd2, et seq. Rac2, ↓Igf1
Apoptosis Ptpn13 ↑ 1.3 (0.22) Ngfr, *↑Ptpn13 ↓ ‒1.6 (0.09) Ctsh
Focal adhesion ↑ 1.6 (0.09) Tnxb, ↑Vwf, ↑Ccnd2, ↑Flnc ↑ 1.8 (< 0.05) Tnc, ↑Flnc, ↑Col1a2, ↑Col1a1, ↑Col6a2, ↑Lama5, *↑Ccnd2, ↑Thbs2, ↑Col6a1 ↓ ‒1.3 (0.22) Spp1, ↓Rac2, ↓Igf1
HIF-1 signaling pathway ↓ ‒1.8 (< 0.05) Pgk1, ↓Pdk1, ↓Egln3, ↓Slc2a1 *↓Egln3 ↑ 1.5 (0.10) Hk2
mTOR signaling pathway ↓ ‒1.4 (0.15) Rragd ↑ 1.6 (0.07)
Notch signaling pathway ↑ 1.5 (0.13) ↑ 1.7 (< 0.05) Jag2
PPAR signaling pathway ↑ 2.0 (< 0.05) Plin4, ↑Fabp4, ↑Scd1 ↑ 1.5 (0.07) *↑Scd1 Lpl, ↓Pltp, ↓Cd36
TGF-beta signaling pathway Dcn, ↑Tgfbr2, ↑Bambi ↑ 1.6 (< 0.05) Nbl1, ↑Id1, ↑Dcn, *↑Tgfbr2, ↑Ltbp1
VEGF signaling pathway ↑ 1.4 (0.13) ↓ ‒1.4 (0.17) Rac2, ↓Mapkapk3
Wnt signaling pathway ↑ 1.7 (0.07) Sfrp2, ↑Ccnd2, ↑Bambi ↑ 2.0 (< 0.05) Tcf7, ↑Serpinf1, ↑Nfatc4, ↑Axin2, *↑Ccnd2 Rac2
DNA replication and repair
DNA replication ↑ 1.5 (0.10) ↓ ‒2.3 (< 0.05)
Fanconi anemia pathway ↓ ‒1.5 (0.11) Polk ↓ ‒1.5 (0.13) #
Homologous recombination ↓ ‒1.4 (0.14)

mRNA sequencing reported for sub-cohorts (n = 3); threshold for pathway enrichment: fdr < 0.25; thresholds for differentially expressed leading-edge genes: Padj < 0.05, log2 fold change ≥ |1|, SEM ≤ 0.5.

(nes) normalized enrichment score; (fdr) false detection rate; (↑↓) up/down-regulation; (→) no change; * gene response shared with [PRRT]; # pathway response shared with [ET+PRRT].